Advertisement
UK markets closed
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • CRUDE OIL

    83.34
    +1.44 (+1.76%)
     
  • GOLD FUTURES

    2,336.30
    -10.10 (-0.43%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • Bitcoin GBP

    53,178.92
    -348.00 (-0.65%)
     
  • CMC Crypto 200

    1,427.69
    +12.93 (+0.91%)
     
  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

Analyst Recommendations for Novo Nordisk in April

Analyst Recommendations for Novo Nordisk in April

In March, Novo Nordisk (NVO) received an exclusive worldwide license for EpiDestiny’s sickle cell disease program, EPI01. Novo Nordisk will pay more than $400 million as an upfront payment to EpiDestiny for the license. EpiDestiny will also receive development and sales milestone payments from Novo Nordisk along with royalties on net sales of the product.